Springer Nature
Browse
1/1
10 files

Metadata and data associated with the published article: Systemic Short Chain Fatty Acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

dataset
posted on 2020-04-21, 12:03 authored by Clélia Coutzac, Jean-Medhi Jouniaux, Angelo Paci, Julien Schmidt, Domenico Mallardo, Atmane Seck, Vahé Asvatourian, Lydie Cassard, Patrick Saulnier, Ludovic Lacroix, Paul-Louis Woerther, Aurore Vozy, Marie Naigeon, Laetitia Nebot-Bral, Melanie Desbois, Ester Simeone, Christine Mateus, Lisa Boselli, Jonathan Grivel, Emilie Soularue, Patricia Lepage, Franck Carbonnel, Paolo Ascierto, Caroline Robert, Nathalie Chaput
This dataset consists of 10 .xlsx spreadsheets containing all source data from the related manuscript.

The spreadsheets are as follows.
- NCOMMS-19-10571A_Raw NGS data.xlsx
This spreadsheet contains summary statistics for all raw Next Generation Sequencing data described in the manuscript. There are 38 tabs of data.
- Data underlying figures 1 to 6 in the related manuscript are included in files with the naming format 'ncomms-source-data Fig X.xlsx'. Each such file contains separate tabs for each sub-figure. Data underlying Figures 1 and 2 are presented in the same spreadsheet.
- Data underlying supplementary figures 1 to 18 of the related manuscript are included in files with the naming format 'ncomms-source-data Supp Fig A_B.xlsx', where A is the first supplementary figure in the spreadsheet, and B is the last. Each such file contains separate tabs for each supplementary figure.

The related publication evaluated whether short chain fatty acid (SCFA) levels could be related to the clinical outcome in mice and in patients treated with anti-CTLA-4 blocking mAbs.

Funding

The study was funded by Gustave Roussy Cancer Campus, Fondation Gustave Roussy, the Institut national de la santé et de la recherche médicale (INSERM), the Centre national de la recherche scientifique (CNRS), SIRIC SOCRATE (INCa DGOS INSERM 6043), SIRIC SOCRATE 2.0 (INCa-DGOS-INSERM_12551), MMO program: ANR-10IBHU-0001); Direction General de l’Offre de Soins (DGOS; TRANSLA 12-174); Institut National du Cancer (INCa; 2012-062 N_ Canceropole: 2012-1-RT-14-IGR-01). Dr. Clélia Coutzac was supported by fellowships from Fondation pour la Recherche Medicale (FRM) from 2015 to 2016.

History

Research Data Support

Research data support provided by Springer Nature